The Justice Department said on Tuesday that it had recommended easing restrictions on marijuana in what could amount to a major change in federal policy.
Even though the move, which kicks off a lengthy rule-making process, does not end the criminalization of the drug, it is a significant shift in how the government views the safety and use of marijuana for medical purposes. It also reflects the Biden administration’s effort to liberalize marijuana policy in a way that puts it more in line with the public as increasingly more Americans favor legalizing the drug.
The decision comes at an opportune time for President Biden, who is trailing the presumptive Republican nominee, former President Donald J. Trump, as they approach the November election, according to a recent CNN poll.
It could also lead to the softening of other laws and regulations that account for the use or possession of cannabis, including sentencing guidelines, banking and access to public housing.
People familiar with the recommendation, speaking on the condition of anonymity, said Attorney General Merrick B. Garland planned to tell the White House Office of Management and Budget that the government should change the drug’s categorization. After the office assesses the recommendation, it will still face a long road before taking effect, including being subject to public comment.
The Associated Press earlier reported the Justice Department decision.
For more than half a century, marijuana has been considered a Schedule I drug, classified on the same level as highly addictive substances like heroin that the Drug Enforcement Administration describes as having no currently accepted medical use. Moving marijuana to Schedule III, as the Department of Health and Human Services recommended in August, would put it alongside less addictive substances like Tylenol with codeine, ketamine and testosterone, meaning that it would be subject to fewer restrictions on production and research, and that it could be prescribed by a doctor.
The recommendation came despite concerns from Anne Milgram, the administrator of the D.E.A., which has long relied on federal research and data to support these decisions, according to a law enforcement official familiar with the matter.
Administration officials have privately acknowledged the political benefit of easing marijuana restrictions: It could energize younger voters dissatisfied with the White House and please criminal justice advocates who have pressed Mr. Biden to overhaul the nation’s drug policy.
While Mr. Biden has been slow to embrace such a change, he has for years said that designating marijuana on the same level as heroin or LSD made little sense. He hinted during his State of the Union address in March that change could soon be coming; about a week later, Vice President Kamala Harris said that the D.E.A. must reassess marijuana “as quickly as possible.”
Support for easing marijuana restrictions has grown over the years, shifting from a point of focus among the left flank of the Democratic Party to becoming a more bipartisan issue. A Gallup poll from November found that 70 percent of Americans believed marijuana use should be legal, an increase from 50 percent in 2013.
Still, the decision will do little to alter the current landscape, with the most immediate impact on the cannabis industry itself.
“A lot of people are going to be disappointed and probably a bit surprised about how very little changes,” said Paul Armentano, deputy director of the advocacy group NORML, the National Organization for the Reform of Marijuana Laws.
Already, 38 states, the District of Columbia and three territories have approved its use for medical reasons. Many of those places have also approved it for recreational use.
But the D.E.A.’s move does not make state laws on using medical marijuana compliant with the federal law.
And for states that have not approved the use of marijuana for medicinal or recreational purposes, downgrading the drug would not automatically change state and local criminal statutes.
The bigger shift, many say, is cultural.
“It is a strong signal that the war on drugs and the crimes that are associated with the war on drugs should continue to be re-evaluated and should continue to be reformed and change,” said Ed Chung, the vice president of initiatives at the nonprofit Vera Institute of Justice, which focuses on criminal justice reform. “There is a huge messaging aspect to that.”
The cannabis industry stands to benefit the most from the recommended change, which would ensure that state-licensed businesses are eligible for a steep tax cut, possibly leading to lower prices for consumers.
This tax relief is estimated to free up millions of dollars for companies to put toward things like hiring, expansion and product development, all of which could be a boon to local economies.
Under tax law, businesses related to controlled substances that are classified in the top two tiers are deemed ineligible for most credits or reductions.
Categorizing marijuana as a Schedule III drug removes such restrictions, allowing plant-touching businesses like cultivators, processors and retailers to claim common deductions for expenses like rent, payroll and marketing.
It is not yet clear how rescheduling would affect businesses’ access to financial services, or the lack thereof. Currently, many cannabis businesses are forced to operate in cash only, because most banks do not want to risk handling cash made from selling an illegal substance under federal law. Doing so is considered money laundering.
Kevin Sabet, who served as a drug policy adviser during the Obama, Bush and Clinton administrations, said the data did not exist to support rescheduling marijuana.
“Politics and industry influence have loomed over this decision from the very beginning,” said Mr. Sabet, now the president of the group, Smart Approaches to Marijuana, which focuses on aligning marijuana policy with scientific research.
The federal government last considered rescheduling marijuana at the end of the Obama administration. Ultimately, the D.E.A. declined to do so, based on a recommendation from the Department of Health and Human Services. At the time, officials cited federal health experts’ assessments that “marijuana has a high potential for abuse, has no accepted medical use in the United States and lacks an acceptable level of safety for use even under medical supervision.”
But in the past decade, more states have moved to decriminalize small amounts of marijuana and make it available for medical use, and the industry has pressured the federal government to revisit that 2016 decision.
During his 2020 campaign, Mr. Biden vowed to decriminalize cannabis and erase convictions over its use, and as president he has moved toward that, issuing pardons and commutations over nonviolent drug offenses. It is a shift for a president who has not supported legalizing marijuana and who as a senator championed aggressive drug laws, including the 1994 crime bill that led to mass incarceration.
In October 2022, Mr. Biden pressed his administration to quickly review the classification of the drug. Less than a year later, the Department of Health and Human Services recommended that marijuana be reclassified from Schedule I to Schedule III.
The decision was leaked, giving the public an unusual look into the agency’s findings. Health officials found that while regular use of marijuana did create a dependence on the drug, “the likelihood of serious outcomes is low.”
Ashley Southall and Andrew Jacobs contributed reporting.
